Loading…
Xencor, Inc. is projected to rise to $12.46 by 2027, a +6% move from its current price of $11.72. XNCR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.34 | $11.72 | $12.10 | -0.03% |
| May 30 | $11.19 | $11.71 | $12.26 | -0.07% |
| May 31 | $11.07 | $11.71 | $12.38 | -0.10% |
| Jun 1 | $10.97 | $11.70 | $12.48 | -0.14% |
| Jun 2 | $10.89 | $11.70 | $12.57 | -0.17% |
| Jun 3 | $10.81 | $11.70 | $12.66 | -0.21% |
| Jun 4 | $10.74 | $11.69 | $12.73 | -0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.74 | $11.69 | $12.73 | -0.24% |
| Week 2 | $10.34 | $11.66 | $13.16 | -0.49% |
| Week 3 | $10.04 | $11.63 | $13.49 | -0.73% |
| Week 4 | $9.79 | $11.61 | $13.76 | -0.97% |
| Week 5 | $9.57 | $11.58 | $14.01 | -1.21% |
| Week 6 | $9.37 | $11.55 | $14.23 | -1.45% |
| Week 7 | $9.20 | $11.52 | $14.44 | -1.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company’s work spans a range of antibody-based therapies and bispecifics, with marketed and development-stage programs aimed at serious conditions.
Its portfolio includes Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder, and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell engager in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies.
The company was incorporated in 1997 and is headquartered in Pasadena, California.
Xencor, Inc. (XNCR) is a healthcare stock that currently ranks 2657 by market cap and has a market capitalization of $838.54M. The stock trades at a current price of $11.31.
The shares sit near the major moving averages, with a 50-day simple moving average (SMA) of $12.21 and a 200-day SMA of $12.50, indicating a price that is hovering around key long-term levels.
Looking ahead, the verified forecast shows a path of gradual appreciation over time, with 2026 a baseline year at a min of $10.41, an average of $11.31, and a max of $14.18; and an upward trajectory into 2030 and beyond, where the average price reaches $14.78 by 2030 and then $24.52 in 2040, rising to $53.13 by 2050. The outlook also notes bullish sentiment beginning in 2030 and highlights headline figures such as a 2030 average of $14.78 with a max of $22.58 and a 2030 ROI of 30.6%, followed by continued strength into 2040 (average $24.52, max $44.53, ROI 116.8%) and 2050 (average $53.13, max $106.84, ROI 369.8%).
A major floor 24.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.2% below — buyers have tended to step in here.
The nearest ceiling, 14.0% above — a clean break opens room to run.
A major ceiling 26.1% above — clearing it would confirm fresh momentum.
Key XNCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XNCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.45 | Buy | $11.51 | Buy |
| MA 10 | $11.42 | Buy | $11.58 | Buy |
| MA 20 | $12.00 | Sell | $11.84 | Sell |
| MA 50 | $12.20 | Sell | $12.15 | Sell |
| MA 100 | $12.36 | Sell | $12.41 | Sell |
| MA 200 | $12.54 | Sell | $12.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.56 | Neutral |
| Stoch RSI (14) | 72.60 | Neutral |
| CCI (20) | -28.32 | Neutral |
| Williams %R (14) | -46.53 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -8.86 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 53.47 | Neutral |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -0.80 | Sell |
| Ultimate (7,14,28) | 52.37 | Neutral |
| Momentum (10) | -0.72 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 11.61 | Buy |
| ADX (14) | 11.39 | Neutral |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is bearish, with an RSI(14) of 40 indicating cooling momentum.
The stock trades around the 50-day moving average of $12.21 and just beneath the 200-day moving average of $12.50, suggesting near-term resistance around those levels.
On the downside, a key support sits at $10.41, while resistance stands at $13.36. The 30-day price range spans from $9.06 to $14.12, highlighting a choppy but range-bound near-term environment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.41 | $11.72 | $14.63 | 0% | Neutral | |
| $9.71 | $12.46 | $17.03 | +6% | Neutral | |
| $8.50 | $11.27 | $16.05 | -4% | Neutral | |
| $9.16 | $12.49 | $18.38 | +7% | Neutral | |
| $11.52 | $16.09 | $24.32 | +37% | Bullish | |
| $12.09 | $17.26 | $26.73 | +47% | Bullish | |
| $12.82 | $18.70 | $29.58 | +60% | Bullish | |
| $12.55 | $18.67 | $30.11 | +59% | Bullish | |
| $11.96 | $18.13 | $29.76 | +55% | Bullish | |
| $13.31 | $20.55 | $34.29 | +75% | Bullish | |
| $16.54 | $27.78 | $49.65 | +137% | Bullish | |
| $30.84 | $60.03 | $118.52 | +412% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.41 | $11.72 | $13.84 | +0.00% |
| June 2026 | $10.03 | $11.83 | $14.31 | +0.90% |
| July 2026 | $9.53 | $11.35 | $13.96 | -3.99% |
| August 2026 | $9.33 | $11.20 | $13.93 | -1.38% |
| September 2026 | $9.48 | $11.45 | $14.39 | +2.27% |
| October 2026 | $9.33 | $11.34 | $14.37 | -1.02% |
| November 2026 | $9.07 | $11.08 | $14.15 | -2.25% |
| December 2026 | $9.26 | $11.37 | $14.63 | +2.65% |
Click any year to see its month-by-month XNCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XNCR to range from $10.41 to $14.63 through 2026. The $11.72 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The XNCR price prediction for 2027 points to an average of $12.46 (low $9.71, high $17.03) — a potential gain of +6% on today's $11.72. A consolidation phase looks the most probable path here.
In 2028, XNCR is projected to trade between $8.50 and $16.05, averaging $11.27 — a potential decline of -4% from today's $11.72. That is -10% versus the projected 2027 average. Price action looks broadly range-bound.
Xencor, Inc.'s 2029 outlook centres on $12.49, within a $9.16 to $18.38 range. That is up +11% on the projected 2028 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, XNCR could reach as high as $24.32, with a base case around $16.09 and support toward $11.52 — roughly +37% from $11.72. Momentum favours further upside here.
Expect XNCR to range from $12.09 to $26.73 through 2031. The $17.26 average target implies a +47% move from current prices. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The XNCR price prediction for 2032 points to an average of $18.70 (low $12.82, high $29.58) — a potential gain of +60% on today's $11.72. Momentum favours further upside here.
In 2033, XNCR is projected to trade between $12.55 and $30.11, averaging $18.67 — a potential gain of +59% from today's $11.72. That is 0% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Xencor, Inc.'s 2034 outlook centres on $18.13, within a $11.96 to $29.76 range. That is -3% versus the projected 2033 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2035, XNCR could reach as high as $34.29, with a base case around $20.55 and support toward $13.31 — roughly +75% from $11.72. Buyers look set to stay in control over this stretch.
Expect XNCR to range from $16.54 to $49.65 through 2040. The $27.78 average target implies a +137% move from current prices. That is up +35% on the projected 2035 average. Momentum favours further upside here.
The XNCR price prediction for 2050 points to an average of $60.03 (low $30.84, high $118.52) — a potential gain of +412% on today's $11.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in XNCR today (≈ 85.324232 XNCR) could be worth
$5,122.2
+$4,122.2 (+412%) by 2050 · US Dollar
Based on the average projected XNCR price of $60.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XNCRwould be worth at today's price.
$1,000 invested in XNCR on May 27, 2025 (≈ 129.032258 XNCR) would be worth
$1,512.26
+$512.26 (+51.2%) today · 1.51× · US Dollar
Based on a XNCR entry price of $7.75 vs. today's $11.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.32 | $1,035.34 | +3.5% |
| 1 month ago | $13.1 | $894.66 | -10.5% |
| 3 months ago | $13.55 | $864.94 | -13.5% |
| 6 months ago | $17.32 | $676.67 | -32.3% |
| 1 year ago | $7.75 | $1,512.26 | +51.2% |
| All time (5.0y) ago | $39.06 | $300.05 | -70.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XNCR forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $1.71B
The multi-year forecast paints a bullish arc after 2029, with the average price rising from $14.78 by 2030 to $24.52 by 2040 and $53.13 by 2050. In 2030 the average price is projected at $14.78 with a max of $22.58 and a ROI of 30.6%, and the sentiment is labeled bullish. By 2040 the average is $24.52 with a max of $44.53 and a ROI of 116.8%, maintaining a bullish view.
In 2050 the average reaches $53.13 with a max of $106.84 and a ROI of 369.8%, continuing the bullish outlook.
Earlier years show more modest dynamics, including neutral to slight-negative moments (for example, 2028 with a max of $15.05 and a negative ROI of -7.4%), underscoring that outcomes are uncertain and not guaranteed. Overall, the long-term forecast signals substantial upside potential if the growth drivers materialize, but also meaningful risk given the varying yearly returns.
Tap a question to reveal the answer.
According to the forecast, 2030 has a min of $10.47, an avg of $14.78, and a max of $22.58, with a ROI of 30.6% and bullish sentiment.
The multi-year view shows a bullish path from 2030 onward (2030 avg $14.78; 2040 avg $24.52; 2050 avg $53.13) with substantial upside potential, but earlier years include neutral to modest returns and some downside risk, so outcomes are not guaranteed.
Yes, the 2050 forecast shows an average price of $53.13 with a max of $106.84 and a bullish sentiment, implying that reaching around $50 is within the projected range for that year.
The short-term view is bearish with RSI(14) at 40. The price is around the 50-day SMA of $12.21 and close to the 200-day SMA of $12.50; support is at $10.41 and resistance at $13.36, with a 30-day range of $9.06 to $14.12.
The current price is $11.31 and the market cap is $838.54M, with a rank of 2657.
Xencor, Inc. Community Discussion
0Share your Xencor, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.